Pan-PI3K inhibitors and PI3Kα inhibitors usually generate severe hyperglycaemia, grade ≥ 3, which was experienced by 23.8% of patients treated with copanlisib (Dreyling et al. 2017a) and 32.7% of patients treated with alpelisib (Rugo et al. 2020). Here, PIK3CA is linked to Hyperglycemia.